Cost-effective management of acute rejection in liver transplant recipients: a managed care perspective

Transplant Proc. 1997 Feb-Mar;29(1-2):1557-9. doi: 10.1016/s0041-1345(96)00673-2.
No abstract available

MeSH terms

  • Acute Disease
  • Antilymphocyte Serum / therapeutic use
  • Biopsy, Needle / economics
  • Cost-Benefit Analysis
  • Cyclosporine / therapeutic use
  • Graft Rejection / economics*
  • Graft Rejection / pathology
  • Graft Rejection / therapy
  • Humans
  • Hyperglycemia / chemically induced
  • Hyperglycemia / drug therapy
  • Hyperglycemia / epidemiology
  • Immunosuppression Therapy / economics*
  • Liver Transplantation / economics*
  • Liver Transplantation / immunology
  • Managed Care Programs / economics*
  • Methylprednisolone Hemisuccinate / adverse effects
  • Methylprednisolone Hemisuccinate / therapeutic use
  • Muromonab-CD3 / therapeutic use
  • Outpatients
  • United States

Substances

  • Antilymphocyte Serum
  • Muromonab-CD3
  • Methylprednisolone Hemisuccinate
  • Cyclosporine